you are here:

Ajanta Pharma Ltd.

BSE: 532331 | NSE: AJANTPHARM |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE031B01049 | SECTOR: Pharmaceuticals

BSE Live

May 12, 16:00
2002.95 60.45 (3.11%)
Volume
AVERAGE VOLUME
5-Day
9,594
10-Day
12,365
30-Day
9,680
6,076
  • Prev. Close

    1942.50

  • Open Price

    1942.50

  • Bid Price (Qty.)

    1991.00 (3)

  • Offer Price (Qty.)

    2002.95 (1)

NSE Live

May 12, 16:00
2005.00 62.05 (3.19%)
Volume
AVERAGE VOLUME
5-Day
279,594
10-Day
292,223
30-Day
214,047
188,951
  • Prev. Close

    1942.95

  • Open Price

    1962.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    2005.00 (329)

Company History - Ajanta Pharma
2005
 -Max Healthcare to establish India`s first brain lab in New Delhi
 -Max India Ltd  Max telecom ventures Ltd signed a MoU
 
 2008
 -Max India signs agreement with UK firm for health insurance biz
 
 2012
 -Board declares Interim Dividend of 500% i.e. Rs. 10/- for every
 equity share of Rs. 2/- each to the shareholders.
 -Ajanta Pharma Ltd has splits its face value from Rs 10/- to 5/-
 
 
 2013
 - Board recommends Final Dividend 610% amounting to Rs. 12.20 per
 equity share of Rs. 2/- each to the shareholders.
 -Ajanta Pharma has announces bonus in the ratio of 1:2
                                                         
 2014
 -Board recommends Final Dividendof 90%, i.e., Rs. 1.80 for every
 equity share of Rs. 2/- each  to the shareholders
 
 2015
 -Ajanta Pharma Announces the Launch of Montelukast Sodium Oral
 Granules 
 -Launch of Montelukast lR Tablets and Montelukast Chewable Tablets in
 US market
 -Fortune India presents award to Ajanta Pharma
 -Ajanta Pharma gets approvals for 3 ANDA's
 -Ajanta Pharma has splits its face value from Rs. 5 to Rs. 2
 
 2017
 -Ajanta Pharma gets USFDA nod for Duloxetine Hydrochloride.
 -Ajanta Pharma launches Eletriptan Hydrobromide Tablets.
 -Ajanta Pharma launches Clonidine Hydrochloride Extended Release
 Tablets in US.
 -Inaugurated & commissioned 1st phase at a New Facility in Guwahati,
 Assam, India
 - Dahej facility receives successful US FDA approval.